Enveric Biosciences develops neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Its news commonly centers on EB-003, a lead candidate from the EVM301 Series designed to promote neuroplasticity without hallucinogenic effects and to modulate 5-HT2A and 5-HT1B receptors. Company updates also discuss preclinical models tied to PTSD, depression, anxiety and related neuropsychiatric conditions.
Recurring announcements include intellectual-property activity for the EVM301 and EVM401 Series, trademark registrations, corporate and financial results, and capital actions involving common stock, pre-funded warrants and other warrants. Enveric also reports business-development and conference activity around non-hallucinogenic and psychedelic-inspired therapeutic approaches.
Enveric Biosciences (NASDAQ: ENVB) has appointed Dr. Marcus Schabacker to its Board of Directors on January 5, 2021. Dr. Schabacker, possessing over 35 years of healthcare experience, is recognized for his work at ECRI Institute and Baxter Healthcare. His expertise aligns with Enveric's mission to develop cannabinoid medicines aimed at improving the quality of life for cancer patients, particularly focusing on treating side effects from cancer therapies. The company aims to leverage Dr. Schabacker's insights to enhance its research and development efforts.